Sanara MedTech

ACTIGEN Verified Inductive Bone Matrix is anaturally derived, differentiated allograft matrixwith robust handling properties.

BiFORM Bioactive Moldable Matrix is a bioactive and osteoconductive bone graft that can be hydrated and used as a strip or molded into a putty to fill a bone defect.

FORTIFY TRG Tissue Repair Graft is a 100% porcine small intestinal submucosa (SIS) ECM intended for implantation to reinforce soft tissue.

OsStic enhances bone integrity to recreate joint surfaces into a composite, load-sharing construct. OsStic technology offers structural support for periarticular fractures, adhesive properties for fracture reduction and provisional fixation, and enables bone remodeling while maintaining stability.

Sanara MedTech follows CDC guidelines to ensure its products remain safe for shipment during the Coronavirus pandemic.

Sanara MedTech completed a $10 million private placement of common stock in Fort Worth, Texas.

The Sanara MedTech Board of Directors guides the company’s focus on innovation and patient-focused solutions.

Sanara MedTech describes its management team and its work to support patient well-being.

Sanara MedTech develops advanced healing solutions and biotechnology to improve patient outcomes.

Sanara MedTech Inc. releases its unaudited financial results for Q2 2026, detailing revenue, expenses, and operational performance. The report highlights key metrics such as net income, growth trends, and strategic initiatives in medical technology. Investors and stakeholders review the data to assess the company’s market position and future outlook.

Aug 2026GlobeNewswireNews article

MIMEDX acquires Sanara MedTech to form a leading regenerative medicine company serving multiple surgical specialties. The deal expands MIMEDX’s product portfolio in orthopedics, spine, sports medicine, and other surgical fields. The combined entity aims to leverage complementary technologies and market reach to strengthen its position in regenerative treatments.

Jul 2026Yahoo FinanceNews article

Sanara MedTech Inc. is exiting its Tissue Health Plus segment after evaluating strategic alternatives. The company will now concentrate exclusively on its surgical business, streamlining operations and resources. This shift follows a review of long-term growth opportunities across its divisions.

Nov 2025BioSpaceNews article

Sanara MedTech Inc. names a new Chief Executive Officer to succeed the outgoing leader. The transition marks a leadership shift within the medical technology company, though no specific successor or details about the outgoing CEO are disclosed in the announcement. The company operates in the medtech sector, focusing on innovative healthcare solutions.

Sep 2025Sanara MedTechNews article